Targeted Retreatment of COPD Exacerbations
NCT02300220
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
144
Enrollment
OTHER
Sponsor class
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
DRUG:
Ciprofloxacin
DRUG:
Placebo
Sponsor
Imperial College London